Market access research for pharma

What market access research covers

Market access research answers a different question from brand research. Brand research asks whether a clinician would choose your product; access research asks whether anyone will pay for it, at what price, with what restrictions, and on what evidence. In scope are reimbursement pathway mapping, comparator and evidence requirement assessment, value message testing, pricing and willingness-to-pay research, budget impact validation, contracting and managed-entry option testing, and post-launch formulary tracking.

Because the respondents control budgets rather than prescriptions, the methods shift accordingly. Sample sizes are small — there are only so many national payers or HTA reviewers in a market — so qualitative depth usually carries more weight than quantitative breadth, with quantitative designs reserved for price sensitivity and trade-off work where a number is genuinely needed.

Who you need to talk to

The access audience is wider than 'payers'. It typically includes national payers and insurers, regional and sub-national budget holders, pharmacy benefit managers where they exist, HTA assessors and the clinical and economic experts who advise them, hospital pharmacy and formulary committee members, hospital finance and procurement, and the clinicians who will have to justify a prescription within whatever restrictions result.

Former decision-makers are particularly valuable here. Serving payers and HTA reviewers often cannot discuss specific pending assessments, whereas someone who recently held the role can explain how the process actually works, what evidence genuinely moved a committee and which arguments fail predictably. In India, add scheme administrators and hospital empanelment managers, because package rates and empanelment conditions shape access as much as any formulary decision.

Payer and HTA interviews

Run the first payer conversations earlier than feels comfortable — ideally while Phase III design is still open. Comparator choice, endpoint selection and subgroup definition are access decisions wearing clinical clothing, and they are nearly impossible to fix once a protocol is locked. Early interviews establish what the relevant comparator will be at launch rather than at the time of design, which is frequently a different product.

Structure these as evidence conversations, not preference conversations. Present the draft value proposition, the planned endpoints and the economic argument, then probe what would have to be true for coverage without restriction, what would trigger a restriction, and what would trigger rejection. Advisory boards work well for the same purpose when you need payers to react to each other, since the disagreement between a national and a regional budget holder is often the most informative part of the session.

Pricing research methods

No single pricing method is sufficient, so combine a sensitivity read with a trade-off read and triangulate. Each has known failure modes, and using two of them makes the corridor far more credible.

Interpret all of it against the access mechanics of each market. A price that clears a sensitivity test is irrelevant if it sits above a reference price, breaches a price control ceiling, or exceeds the package rate a hospital will be reimbursed for the episode of care.

• Van Westendorp price sensitivity — maps a range of acceptable prices, useful as an early boundary but prone to anchoring.
• Gabor-Granger — tests acceptance at specific price points, giving a demand curve for a defined profile.
• Discrete choice and conjoint analysis — isolates how price trades off against efficacy, safety, administration and comparator attributes.
• Threshold and gate analysis with payers — identifies the price at which coverage becomes restricted or refused.
• Budget impact modelling validated with payers — tests affordability at population level, not just price per patient.
• Secondary price benchmarking — list and net price context in reference markets, and scheme or tender rates where applicable.

Testing the value story and dossier

A value dossier that has never been read by someone outside the company is an untested document. Put the core value messages, the evidence summary and the economic model in front of payers and HTA-experienced reviewers before submission, and ask them to argue against it. What you are looking for is which claims they accept without challenge, which they discount, and which they consider unsupported by the evidence you will actually have at launch.

Test the budget impact model the same way. Payers routinely dispute uptake assumptions, eligible population definitions and offset claims, and those disputes are much cheaper to resolve in a research interview than in an assessment. Where offsets depend on avoided hospitalisation or displaced treatment, expect scepticism and plan for the evidence that would reduce it.

Evidence requirements and HTA expectations

HTA bodies assess relative value against a defined comparator, and their expectations differ in ways that change study design: which comparator is considered standard of care, whether indirect comparison is acceptable, how quality-of-life evidence is weighted, whether real-world evidence is admissible, and how uncertainty is handled. Research should establish those expectations market by market rather than assume a common standard.

Two recurring gaps are worth researching explicitly. The first is comparator drift: the standard of care at submission may not be the one the trial used, and payers will assess against the former. The second is subgroup credibility — a restricted indication is often the realistic access outcome, so test early whether the subgroup you would accept is one an assessor would consider pre-specified and clinically coherent.

Access in India and emerging markets

Access logic in India differs structurally from US or European models. A large share of retail medicine spending is out of pocket, so affordability sits with the patient and family and the prescriber's awareness of their circumstances. Public funding concentrates on hospitalisation through Ayushman Bharat PM-JAY and state schemes, where package rates set hard economic boundaries for what a hospital will adopt, and empanelment conditions govern where care is delivered.

Price control adds a further constraint: the National List of Essential Medicines and the Drugs (Prices Control) Order set ceiling prices for scheduled formulations. Questions written around formulary tiers, prior authorisation and rebate structures therefore map poorly. Replace them with research into out-of-pocket affordability, scheme package rates, tender and rate contract dynamics, hospital procurement behaviour and patient assistance mechanics.

Common mistakes

The most expensive mistake is timing: commissioning access research after trial design is fixed, which converts it from a decision input into an explanation of a constraint. The second is talking only to national payers when regional or hospital-level budget holders control the real decision. The third is treating pricing as a single question with a single method, which produces a number nobody will defend in a negotiation.

Two more recur. Transplanting one market's payer architecture into another's discussion guide generates articulate answers to questions that do not apply. And presenting payers with a value story built on the trial's primary endpoint, when the comparator and the decision-relevant outcome have both moved on, invites a rejection that the research was commissioned to prevent.